Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-ASC-SHEET in Dystrophic Epidermolysis Bullosa
NCT05157958Phase 2Recruiting
- Sponsor
- Anterogen Co., Ltd.
- Start
- May 2023
- Primary completion
- Oct 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allo-asc in dystrophic epidermolysis bullosa (DEB), sponsored by Anterogen Co., Ltd.. Started May 2023; status: recruiting.
02
Drugs
allo-asc
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT05157958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157958.